Allena Pharmaceuticals Inc (NASDAQ:ALNA) shot up 10% on Monday . The company traded as high as $1.24 and last traded at $1.21. 1,092,559 shares were traded during trading, an increase of 40% from the average session volume of 779,695 shares. The stock had previously closed at $1.10.
Several equities research analysts have recently weighed in on ALNA shares. Roth Capital reissued a “market perform” rating and issued a $11.00 target price on shares of Allena Pharmaceuticals in a research report on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating on shares of Allena Pharmaceuticals in a research note on Thursday, September 10th. Wedbush reissued a “buy” rating and issued a $18.00 price objective on shares of Allena Pharmaceuticals in a report on Thursday, September 10th. Zacks Investment Research raised shares of Allena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research note on Thursday, May 21st. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $8.00 target price on shares of Allena Pharmaceuticals in a research note on Wednesday, July 15th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $8.61.
The stock has a market cap of $46.12 million, a price-to-earnings ratio of -0.81 and a beta of 2.68. The stock’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.52. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.21 and a quick ratio of 4.21.
Allena Pharmaceuticals (NASDAQ:ALNA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. As a group, analysts predict that Allena Pharmaceuticals Inc will post -0.95 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in ALNA. Advisor Group Holdings Inc. grew its position in shares of Allena Pharmaceuticals by 81.8% in the 2nd quarter. Advisor Group Holdings Inc. now owns 20,000 shares of the company’s stock valued at $32,000 after purchasing an additional 9,000 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Allena Pharmaceuticals during the second quarter worth about $44,000. Wedbush Securities Inc. grew its stake in Allena Pharmaceuticals by 103.5% in the second quarter. Wedbush Securities Inc. now owns 49,150 shares of the company’s stock valued at $78,000 after purchasing an additional 25,000 shares in the last quarter. Worth Venture Partners LLC grew its position in shares of Allena Pharmaceuticals by 148.1% in the 2nd quarter. Worth Venture Partners LLC now owns 255,000 shares of the company’s stock valued at $403,000 after acquiring an additional 152,206 shares during the period. Finally, Morgan Stanley increased its stake in shares of Allena Pharmaceuticals by 56.1% during the 1st quarter. Morgan Stanley now owns 1,253,847 shares of the company’s stock worth $1,207,000 after purchasing an additional 450,688 shares during the last quarter. 35.14% of the stock is owned by institutional investors.
Allena Pharmaceuticals Company Profile (NASDAQ:ALNA)
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.